CCM
MREO

CAAS Capital Management’s Mereo BioPharma MREO Stock Holding History

CAAS Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,000
Closed -$34K – 1189
2021
Q1 		$34K Buy
+10,000
New +$35.3K ﹤0.01% 1119

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAAS Capital Management's MREO Position: Q2 2021 in Review

CAAS Capital Management sold out of Mereo BioPharma (MREO) in Q2 2021, closing a stake of 10,000 shares — an estimated $34K sold.

CAAS Capital Management first reported a position in MREO in Q1 2021 and held it in 1 quarter. The position peaked at $34K in Q1 2021. 71 funds tracked by Wall St. Rank hold MREO as of Q2 2021.

  • CAAS Capital Management reported no remaining Mereo BioPharma position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 10,000 Mereo BioPharma shares in Q2 2021, an estimated $34K.
  • CAAS Capital Management first reported a position in Mereo BioPharma in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Mereo BioPharma position peaked at $34K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.